Search Results - "Thompson, Aliza M"

Design of Clinical Trials in Acute Kidney Injury: Report from an NIDDK Workshop on Trial Methodology by Palevsky, Paul M, Molitoris, Bruce A, Okusa, Mark D, Levin, Adeera, Waikar, Sushrut S, Wald, Ron, Chertow, Glenn M, Murray, Patrick T, Parikh, Chirag R, Shaw, Andrew D, Go, Alan S, Faubel, Sarah G, Kellum, John A, Chinchilli, Vernon M, Liu, Kathleen D, Cheung, Alfred K, Weisbord, Steven D, Chawla, Lakhmir S, Kaufman, James S, Devarajan, Prasad, Toto, Robert M, Hsu, Chi-yuan, Greene, Tom, Mehta, Ravindra L, Stokes, John B, Thompson, Aliza M, Thompson, B Taylor, Westenfelder, Christof S, Tumlin, James A, Warnock, David G, Shah, Sudhir V, Xie, Yining, Duggan, Emily G, Kimmel, Paul L, Star, Robert A

“…Acute kidney injury (AKI) remains a complex clinical problem associated with significant short-term morbidity and mortality and lacking effective pharmacologic…”
Get full text

Design of Clinical Trials in Acute Kidney Injury: A Report from an NIDDK Workshop—Prevention Trials by Okusa, Mark D, Molitoris, Bruce A, Palevsky, Paul M, Chinchilli, Vernon M, Liu, Kathleen D, Cheung, Alfred K, Weisbord, Steven D, Faubel, Sarah, Kellum, John A, Wald, Ron, Chertow, Glenn M, Levin, Adeera, Waikar, Sushrut S, Murray, Patrick T, Parikh, Chirag R, Shaw, Andrew D, Go, Alan S, Chawla, Lakhmir S, Kaufman, James S, Devarajan, Prasad, Toto, Robert M, Hsu, Chi-yuan, Greene, Tom H, Mehta, Ravindra L, Stokes, John B, Thompson, Aliza M, Thompson, B Taylor, Westenfelder, Christof S, Tumlin, James A, Warnock, David G, Shah, Sudhir V, Xie, Yining, Duggan, Emily G, Kimmel, Paul L, Star, Robert A

“…AKI is an important clinical problem that has become increasingly more common. Mortality rates associated with AKI remain high despite advances in supportive…”
Get full text

Design of Clinical Trials in AKI: A Report from an NIDDK Workshop. Trials of Patients with Sepsis and in Selected Hospital Settings by Molitoris, Bruce A, Okusa, Mark D, Palevsky, Paul M, Chawla, Lakhmir S, Kaufman, James S, Devarajan, Prasad, Toto, Robert M, Hsu, Chi-yuan, Greene, Tom H, Faubel, Sarah G, Kellum, John A, Wald, Ron, Chertow, Glenn M, Levin, Adeera, Waikar, Sushrut S, Murray, Patrick T, Parikh, Chirag R, Shaw, Andrew D, Go, Alan S, Chinchilli, Vernon M, Liu, Kathleen D, Cheung, Alfred K, Weisbord, Steven D, Mehta, Ravindra L, Stokes, John B, Thompson, Aliza M, Thompson, B Taylor, Westenfelder, Christof S, Tumlin, James A, Warnock, David G, Shah, Sudhir V, Xie, Yining, Duggan, Emily G, Kimmel, Paul L, Star, Robert A

“…AKI remains an important clinical problem, with a high mortality rate, increasing incidence, and no Food and Drug Administration-approved therapeutics…”
Get full text

Real World Data and Evidence: Support for Drug Approval: Applications to Kidney Diseases by Thompson, Aliza M, Southworth, Mary Ross

Get full text

Erythropoiesis-Stimulating Agents — Time for a Reevaluation by Unger, Ellis F, Thompson, Aliza M, Blank, Melanie J, Temple, Robert

“…Randomized trials have endeavored to show that using ESAs to raise hemoglobin concentrations to higher targets improves clinical outcomes in patients with…”
Get full text

Validation of an oscillometric home blood pressure monitor in an end-stage renal disease population and the effect of arterial stiffness on its accuracy by Thompson, Aliza M, Eguchi, Kazuo, Reznik, Michael E, Shah, Samir S, Pickering, Thomas G

“…Increased arterial stiffness, common in end-stage renal disease patients, has been shown to affect the correspondence between oscillometric and mercury…”
Get full text

Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC) by Smith, Kimberly A., Thompson, Aliza M., Baron, David A., Broadbent, Steven T., Lundstrom, Gary H., Perrone, Ronald D.

“…Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease. Expansion of multiple cysts throughout both kidneys is…”
Get full text

Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting by Sahre, Martina D., Milligan, Lauren, Madabushi, Rajanikanth, Graham, Richard A., Reynolds, Kellie S., Terzic, Andre, Benjamin, Jessica, Burckart, Gilbert J., Huang, Shiew‐Mei, Schuck, Robert, Thompson, Aliza M., Zineh, Issam

“…Patients with multiple chronic conditions, including more advanced chronic kidney disease (CKD), are often excluded from clinical trials, creating challenges…”
Get full text

Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation by Yao, Xiaoxi, Inselman, Jonathan W., Ross, Joseph S., Izem, Rima, Graham, David J., Martin, David B., Thompson, Aliza M., Ross Southworth, Mary, Siontis, Konstantinos C., Ngufor, Che G., Nath, Karl A., Desai, Nihar R., Nallamothu, Brahmajee K., Saran, Rajiv, Shah, Nilay D., Noseworthy, Peter A.

“…Patients with atrial fibrillation and severely decreased kidney function were excluded from the pivotal non-vitamin K antagonist oral anticoagulants (NOAC)…”
Get full text

FDA Regulatory Perspectives for Studies on Hemodialysis Vascular Access by Hurst, Frank P, Lee, Robert E, Thompson, Aliza M, Pullin, Brian D, Silverstein, Douglas M

“…In an effort to foster innovation and new product development, the American Society of Nephrology and the US Food and Drug Administration partnered to form the…”
Get full text

Glomerular Diseases: Registries and Clinical Trials by Moxey-Mims, Marva M, Flessner, Michael F, Holzman, Lawrence, Kaskel, Frederick, Sedor, John R, Smoyer, William E, Thompson, Aliza M, Yao, Lynne

“…Nephrology has conducted few high-quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for…”
Get full text

Endogenous and Exogenous Vasopressin during Hemodialysis by Thompson, Aliza M., Oliver, Juan A.

“…Intradialytic hypotension likely results from hypovolemia as well as patient and dialysis‐specific factors. An impaired vasoconstrictive response to volume…”
Get full text

Accuracy and precision of the Tomey ViVA infrared photorefractor by THOMPSON, A. M, LI, T, PECK, L. B, HOWLAND, H. C, COUNTS, R, BOBIER, W. R

“…The Fortune Optical (Tomey ViVA) VRB-100 video refractor was tested to determine its accuracy and precision in measuring manifest refractions of human eyes…”
Get full text

GFR Decline as an End Point in Trials of CKD: A Viewpoint From the FDA by Thompson, Aliza, MD, Lawrence, John, PhD, Stockbridge, Norman, MD, PhD

Get full text

Reevaluating Erythropoiesis-Stimulating Agents by Kestenbaum, Bryan

“…To the Editor: A pervasive view holds that any toxicity of erythropoiesis-stimulating agents (ESAs), the topic of the Perspective article by Unger et al. (Jan…”
Get full text